Essais liés13clinical trials
VilleGdansklocalisation
PaysPolandlocalisation
SourcelocaleCSV/MySQL

Informations

centre

Synchronisé depuis ClinicalTrials.gov — NCT03832998

Ouvrir le site du centre

Essais cliniques associés

13
MoléculeIndication / populationPhaseNCTTitreStatut
Soticlestat Épilepsie Phase 3 NCT04940624 A Study of Soticlestat as an Add-on Therapy in Children and Young Adults With Dravet Syndrome COMPLETED
Soticlestat Épilepsie Phase 2 NCT03635073 Endymion 1 — A Study of Soticlestat in Adults and Children With Rare Epilepsies TERMINATED
Soticlestat Épilepsie Phase 3 NCT05163314 A Study of Soticlestat as an Add-on Therapy in Children and Adults With Dravet Syndrome or Lennox-Gastaut Syndrome TERMINATED
Soticlestat Épilepsie Phase 3 NCT04938427 A Study of Soticlestat as an Add-on Therapy in Children, Teenagers, and Adults With Lennox-Gastaut Syndrome COMPLETED
Amivantamab Cancer Phase 3 NCT04538664 PAPILLON — A Study of Combination Amivantamab and Carboplatin-Pemetrexed Therapy, Compared With Carboplatin-Pemetrexed, in Participants With Advanced or Metastatic Non-Small Cell Lung Cancer Characterized by Epidermal Growth Factor Receptor (EGFR) Exon 20 Insertions ACTIVE_NOT_RECRUITING
Erenumab Dose 1 Migraine Phase 3 NCT03832998 OASIS(CM) — Efficacy and Safety of Erenumab in Pediatric Subjects With Chronic Migraine COMPLETED
Trontinemab Alzheimer Phase 3 NCT07170150 TRONTIER 2 — A Clinical Trial of Trontinemab in Participants With Early Symptomatic Alzheimer's Disease RECRUITING
Nipocalimab Myasthénie Phase 2/3 NCT05265273 A Study of Nipocalimab in Children Aged 2 to Less Than 18 Years With Generalized Myasthenia Gravis RECRUITING
Satralizumab Myopathies Phase 2 NCT06450639 SHIELD DMD — A Study to Assess the Efficacy and Safety of Satralizumab in Duchenne Muscular Dystrophy (DMD) ACTIVE_NOT_RECRUITING
Obinutuzumab Lupus Phase 2 NCT05039619 POSTERITY — A Study to Evaluate the Efficacy, Safety, and Pharmacokinetics of Obinutuzumab in Adolescents With Active Class III or IV Lupus Nephritis and the Safety and PK of Obinutuzumab in Pediatric Participants RECRUITING
Erenumab Dose 1 Migraine Phase 3 NCT03836040 OASIS(EM) — Efficacy and Safety of Erenumab in Pediatric Participants With Episodic Migraine ACTIVE_NOT_RECRUITING
Efgartigimod IV Myasthénie Phase 2 NCT04833894 ADAPT Jr — Evaluating the Pharmacokinetics, Pharmacodynamics, and Safety of Efgartigimod Administered Intravenously in Children With Generalized Myasthenia Gravis RECRUITING
Fenebrutinib SEP Phase 2 NCT07161258 FENerations1 — A Pharmacokinetics (PK), Pharmacodynamics (PD), Safety and Tolerability Study of Fenebrutinib in Children and Adolescents With Relapsing Multiple Sclerosis (RMS) RECRUITING